SecBot SecBot

New Era of Preventing End-Stage Kidney Disease Act

H.R. 6790 Rep. Gus Bilirakis (R-FL-12) In committee
Bill text PDF
  1. Introduced Dec 14
  2. Committee Dec 14
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Dec 14, 2023Next: House vote
680d ago Dec 17, 2024: Referred to the Subcommittee on Health.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
2companies, 3 filings
Subscribe to see spend
Member trades
0trades in the last 90 days
None in these companies
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

2 companies
Companies by sector
Biotech & Pharma 2
Search all 2 companies, their asks and price moves Subscribe

Summary

This bill amends the Public Health Service Act to prevent end-stage kidney disease, focusing on rare kidney diseases. It establishes research centers, mandates studies on testing and treatment, expands provider education, and directs experiments on delaying dialysis or transplant.

Sec. 2, Centers of Excellence on Rare Kidney Disease Research: The Director of the National Institute of Diabetes and Digestive and Kidney Diseases may fund regional centers of excellence for rare kidney diseases, including primary glomerular disease. These centers conduct research on causes and treatments, raise public awareness especially in rural and underserved communities, and develop clinical research resources. Support is for up to 5 years, extendable by 5-year periods after peer review. $6 million per year is authorized for fiscal years 2024 through 2028.

Sec. 3, Understanding and Slowing Progression Through Early Intervention, Testing, and Treatment: The Secretary must study testing, preventative care, precision medicine, and treatment for rare kidney disease, reviewing topics like routine urinalysis impact, kidney biopsy reliability, genetic testing utility (including APOL1 gene), barriers to testing, social and biological factors, treatment patterns under Medicare and Medicaid, access to nephrologists, efforts to slow disease progression, and patient trust. A report with recommendations is due to Congress within 18 months, developed in consultation with stakeholders. $1 million per year is authorized for fiscal years 2024 through 2028.

Sec. 4, Provider Education: Primary care training under the Public Health Service Act is amended to include individuals with kidney disease, including rare kidney disease. Nephrology fellowship provisions are added to allow awards for postgraduate training in nephrology, focusing on increasing knowledge of rare kidney disease prevention and treatment for disproportionately impacted populations, improving care quality for racial and ethnic minorities, and increasing the number of trained nephrologists.

Sec. 5, Delaying Kidney Disease Impact: The Social Security Act is amended to require the Secretary to conduct experiments evaluating treatments for rare kidney disease that delay or eliminate the need for dialysis and transplant. The Secretary must also study methods to increase public awareness of rare kidney disease. A report with legislative recommendations is due to Congress within 24 months of enactment.

Summary of the bill text as introduced in House (Dec 14, 2023), generated by SecBot from the official bill text; the Library of Congress summary is not yet published.

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.